The US Food and Drug Administration has approved Bristol Myers Squibb's new oral drug for advanced multiple myeloma, marking the first approval in a novel class of medicines targeting the blood cancer. The therapy, known as mezigdomide, offers a new treatment option for patients who have exhausted other therapies. This milestone reflects ongoing progress in developing more effective and convenient treatments for multiple myeloma, a disease that remains challenging to manage in its advanced stages.
The US Food and Drug Administration has approved mezigdomide, an oral treatment developed by Bristol Myers Squibb, for patients with advanced multiple myeloma. This approval introduces the first drug in a new class of cereblon E3 ligase modulators, designed to target the disease through a novel mechanism.
Mezigdomide is indicated for patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody. The drug's approval is based on data from the Phase 1/2 CC 92480 MM 001 trial, which demonstrated promising efficacy in heavily pretreated patients.
DISCUSSION (0)